Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma
长期随访结果表明，对于TP53改变的复发/难治性B细胞非霍奇金淋巴瘤，单独使用或联合自体干细胞移植的双重CD19/CD22 CAR-T细胞疗法具有治愈潜力。
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02571-7
Mao, Zekai; Peng, Juan; Cao, Yang; Wang, Na; Wang, Jue; Yang, Yang; Xu, Jinghuan; Meng, Fankai; Chen, Liting; Mao, Xia; Guo, Jiaqi; Zhou, Xiaoxi; Zhang, Yicheng; Wei, Jia
B细胞
发育与干细胞
T细胞
淋巴瘤
CD22
T细胞
P53
干细胞
细胞生物学
CD2
CD19
免疫/内分泌
